my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
We contribute to improve cancer diagnostics
The number of people suffering from cancer is constantly growing. A key factor in ensuring patients the best treatment is to make an accurate and full diagnosis and choose the right form of treatment at an early stage.
As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab, an investigational immune checkpoint inhibitor, the companies have announced that they have a collaboration agreement in place with Dako, an Agilent Technologies company, for the ... > more
Agilent Technologies Inc. and EQT, the Sweden-based private equity group, announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history. “In ... > more
Dako announced it has entered into a broad framework agreement with Bristol-Myers Squibb Company on the development of pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb. ... > more
Merck and Pfizer Collaborate with Dako
As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab, an investigational immune checkpoint inhibitor, the companies have announced that they have a collaboration agreement in place with Dako, an Agilent Technologies company, for the ... more
Agilent to Acquire Dako for $2.2 Billion
Agilent Technologies Inc. and EQT, the Sweden-based private equity group, announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history. “In ... more
Dako Enters New Collaboration with Bristol-Myers Squibb on Pharmacodiagnostics
Dako announced it has entered into a broad framework agreement with Bristol-Myers Squibb Company on the development of pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb. ... more
Dako is one of the world's leading companies in cancer diagnostics. We develop, manufacture and market cell-based cancer diagnostics for both clinical diagnostics and research use. more
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako’s reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako became part o ... more
© 1997-2018 LUMITOS GmbH, All rights reserved
